Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Chief Medical Officer | July 31, 2025 | August 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date July 31, 2025 · Filed August 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 16,087 |
Reported balance
After 2025-07-31 transaction · row 1
1 source rowRow 1 · 2025-07-31 · Grant · Acquired 2,018 · Balance 16,087 F1: These shares were purchased due to participation of the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2025 through July 31, 2025. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock. |
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectBy Matthew Scott Harris Trust | 67,787 |
Reported balance
Holding disclosure · report date 2025-07-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 67,787 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased due to participation of the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2025 through July 31, 2025.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,800 | $6.86 | $12,348.00 |
DisclosureSEC source: 0001104659-22-011519 · tm225504-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,562 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2021 through January 31, 2022. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2022. Read SEC document |
| July 31, 2021 Filed Aug 6, 2021 23:02 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 725 | $7.71 | $5,589.39 |
DisclosureSEC source: 0001104659-21-101663 · tm2124283-3_4seq1.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2021 through July 31, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2021. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 24,664 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004757 · doc4.xml · derivative · entry 3 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,664 Underlying: Common Stock, par value $0.0001 · 24,664 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 90,000 | $0.00 Strike: $16.71 | $0.00 |
DisclosureSEC source: 0000899243-21-004757 · doc4.xml · derivative · entry 2 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock, par value $0.0001 · 90,000 shares Expires 2031-02-01 F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 1, 2022 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 31, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 968 | $12.14 | $11,751.52 |
DisclosureSEC source: 0000899243-21-004757 · doc4.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,037 F1 · kind: These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2020 through January 31, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2021. Read SEC document |
| November 12, 2020 Filed Nov 13, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 4,015 | $10.02 | $40,230.30 |
DisclosureSEC source: 0000899243-20-031029 · doc4.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,069 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $10.16, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 8,084 | $1.46 | $11,802.64 |
DisclosureSEC source: 0000899243-20-021219 · doc4.xml · nonDerivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,084 F1 · kind: These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2020 through July 31, 2020. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 1, 2020. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:01 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 61,400 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-20-000276 · doc4.xml · derivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,400 Underlying: Common Stock, par value $0.0001 · 61,400 shares Expires 2030-01-02 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 20:07 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 107,000 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0000899243-19-023318 · doc4.xml · derivative · entry 1 Harris Matthew Scott · CIK 0001787762 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock, par value $0.0001 · 107,000 shares Expires 2029-09-09 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on September 9, 2020 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following September 9, 2020, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.